Risk Factors For The Presence Of Artemisinin Antibodies Amongst Patients Undergoing Treatment For Malaria In Benin City, Nigeria

##plugins.themes.bootstrap3.article.main##

  •   Helen Oroboghae Ogefere

  •   Nosakhare Lawrence Idemudia

  •   Richard Omoregie

Abstract

Artemisinin have being used for the control of malaria worldwide for over a decade and its listing by WHO as the first-line drug for treatment of both severe and uncomplicated malaria and the observed treatment failure have warranted the need to screening malaria patients for the presence of antibodies to malaria. In our locality where there is unregulated use of antimicrobials, the need to ascertain the prevalence of antibodies to artemisinin and evaluate the potential risk factors cannot be overemphasised, hence this study. Blood specimens were collected from 400 randomised patients undergoing treatment for malaria in Benin City, Nigeria. Data on socio-demography were collected with the aid of a well-structured questionnaire. Artemisinin antibodies were detected by drug absorption mechanism (DAM) and immune complex reaction (IMC) methods. ABO, rhesus blood group, and haemoglobin (Hb) phenotype were determined by using standard technique. A total of 112(28.00%) out of the 400 participants had artemisinin antibodies. Gender, marital status, level of education, residential area and living arrangement did not significantly affect the prevalence of artemisinin antibodies whereas age and ethnicity significantly affected the prevalence of artemisinin antibodies (p=0.0244 and 0.0001 respectively). Duration of the last artemisinin used and the mostly used brand of artemisinin as well as the ABO and rhesus blood groups and haemoglobin phenotypes did not significantly affect the production of artemisinin antibodies. Although of all the risk factors age and ethnicity were identified as the only risk factors for the development of artemisinin, we therefore advocate the prudent use of artemisinin-containing antimalarial and concerted efforts in combating self-medication with this drugs to avoid the development of resistance.


Keywords: Artemisinin, Antibodies, Prevalence, Risk factors

References

WHO. World malaria report. World Health Organization: Geneva. 2013.

WHO. World malaria report. World Health Organization: Geneva. 2017.

Federal Ministry of Health (FMoH). National guidelines for diagnosis and treatment of malaria 2015. Abuja, Nigeria: FMoH. 2015.

Centre for Disease Control and Prevention (CDC) Malaria. Global Health, Division of Parasitic Diseases and Malaria. U.S. Department of Health & Human Services, USA.gov 2020.

S.C. Murphy and J.G. Breman. Gaps in the Childhood Malaria Burden in Africa: Cerebral Malaria, Neurological sequelae, anaemia, respiratory distress, hypoglycemia, and complication of pregnancy. Am J Trop Med Hyg vol. 64, no. 1, pp. 57-67, Jan. 2001.

B.H. Oladeinde, R. Omoregie, E.O. Osakue, and T.O. Onaiwu. Asymptomatic malaria among blood donor in Benin City, Nigeria. Iran J Parasitol vol 9, no. 3, pp. 415-422, Sep. 2014.

R. M. Packard. The origins of antimalarial-drug resistance. New England Journal of Medicine vol. 371, pp. 397-399, 2012.

E.A. Ashley, M. Dhorda, R. M. Fairhurst, C. Amaratunga, P. Lim, S. Suon et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine. vol. 371, no. 5 pp. 411-423, Jul. 2014.

K. M. Tun, M. Imwong, K. M. Lwin, A. A. Win, T. M. Hlaing, T. Hlaing et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. The Lancet Infectious Diseases. vol. 15, no. 4, pp. 415-421, Apr. 2015.

I. N. Okeke, A. Lamikanra and R. Edelman. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis vol. 5, no. 1, pp.18-27, Jan-Feb 1999.

R. Omoregie and N. O. Eghafona. Urinary tract infection among asymptomatic HIV patients in Benin City, Nigeria. Br J Biomed Sci vol. 66, no. 4 pp.190-193, 2009.

D. O. Ogbolu. Impact of ESBLs and CREs the Nigeria experience. APUA New Letter vol. 31, no. 2, pp. 15-16, Sep 2013.

L. D. Elam-Evans, D. Yankey, J. A. Singleton and M. Kolasa. National, state, and selected local area vaccination coverage among children aged 19–35 months—United States, 2013. MMWR vol. 63, no. 34, p. 741, Aug 2014.

L. Raffray, M. C. Receveur, M. Beguet, P. Lauroua, T. Pistone and D. Malvy. Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report. Malar. J. vol. 13, no. 1, p. 398, Dec 2014.

M. Charles, J. M. Patterson, L. Asadi and S. Houston. Delayed hemolysis after parenteral artesunate therapy for severe malaria in two returning Canadian travelers. Am J Trop Med Hyg vol. 93, no. 4, pp. 819-821, Oct 2015.

S. Jauréguiberry, M. Thellier, P. A. Ndour, F. Ader, C. Roussel, R. Sonneville et al. Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011–2013. Emerg. Infect. Dis. vol. 21, no. 5, p. 804, May 2015.

R. Zhou, C. Yang, S. Li, Y. Zhao, Y. Liu, D. Qian et al. Molecular surveillance of drug resistance of Plasmodium falciparum isolates imported from Angola in Henan Province, China. Antimicrobial agents and chemotherapy. vol 1, no. 63, pp. e00552-519, Oct 2019.

K. Ikuoyogie, H. O. Ogefere and R. Omoregie. Prevalence and risk factors for sulfadoxine antibody among patients undergoing treatment for malaria in Benin City, Nigeria. Oman Medical Journal. vol. 32, no. 3, pp. 207-213, May, 2017. DOI: 10.5001/omj.2017.39.

F. O. Akinbo, P. J. Anate, D. B. Akinbo, R. Omoregie, S. Okoosi, A. Abdulsalami et al. Prevalence of malaria among HIV patients on highly active antiretroviral therapy in Kogi State, North Central Nigeria. Ann. Nig. Med. vol. 10, no. 1, p. 11, Jan 2016.

M. A. Emokpae and L. B. Akpologun. The use of atherogenic index of plasma in assessing the potential cardiovascular risk among ABO blood groups in sickle cell disease patients. Malay J Med Bio Res vol. 2, no. 3 pp. 247-251, 2015.

R. Omoregie, H. O. Ogefere, E. U. Omokaro and E. Omorogbe. Distribution of ABO and rhesus blood group and haemoglobin phenotypes among tuberculosis patients in Benin City, Nigeria. J Med Lab Sci vol. 11, no. 1, pp. 68-70. 2002.

C. C. Ezenduka, B. O. Ogbonna, O. I. Ekwunife, M. J. Okonta and C. O. Esimone. Drugs use pattern for uncomplicated malaria in medicine retail outlets in Enugu urban, southeast Nigeria: implications for malaria treatment policy. Malar J. vol. 13, no. 1, p. 243, Dec 2014. https://doi.org/10.1186/1475-2875-13-243

V. I. Carrara, S. Sirilak, J. Thonglairuam, C. Rojanawatsirivet, S. Proux, V. Gilbos et al. Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Medicine. vol. 3, no. 6, p. e183, Dec 2014. doi:10.1371/journal.pmed.0030183

N. M. Douglas, N. M. Anstey, B. J. Angus, F. Nosten and R. N. Price. Artemisinin combination therapy for vivax malaria. The Lancet infectious diseases. vol. 10, no. 6 pp. 405-416, Jun 2010.

World Health Organization. Guidelines for the treatment of malaria. World Health Organization; Aug 2015.

F. Nosten, M. Van Vugt, R. Price, C. Luxemburger, K. L. Thway, A. Brockman et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. The Lancet. vol. 356, no. 9226, pp. 297-302, July 2000.

A. Bhattarao, A. S. Ali, S. P. Kachur, A. Martensson, A. K. Abbas, R. Khatib et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med vol. 4, pp. e309, 2007. doi: 10.1371/journal.pmed.0040309.

D. Sinclair, B. Zani, S. Donegan, P. Olliaro and P. Garner. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. vol. 3, pp. CD007483, 2009.

N. U. Igboeli, C. V. Ukwe and O. I. Ekwunife. Increasing use of artemisinin-based combination therapy for treatment of malaria infection in Nigerian hospitals. Pharmacy practice. vol. 8, no. 4, p. 243, Oct 2009. https://doi.org/10.4321/s1886-36552010000400007

R. Adisa, T. O. Fakeye and D. Dike. Evaluation of adverse drug reactions to artemisinin-based combination therapy in a Nigeria university community. Tropical Journal of Pharmaceutical Research. vol. 7, no. 2, pp. 937-944, 2008.

F. Kurth, T. Lingscheid, F. Steiner, M. S. Stegemann, S. Bélard, N. Menner et al. Hemolysis after oral artemisinin combination therapy for uncomplicated Plasmodium falciparum malaria. Emerging infectious diseases. vol. 22, no. 8, pp. 1381–1386, Aug 2016. https://doi.org/10.3201/eid2208.151905

S. Singh, S. K. Singh, A. K. Tentu, A. Kumar, B. Shahbabu, V. Singh et al. Artesunate-induced severe autoimmune hemolytic anemia in complicated malaria. Indian Journal of Critical Care Medicine vol. 22, no. 10, pp. 753-756, Oct 2018. https://doi.org/10.4103/ijccm.IJCCM_298_18

A. Corpolongo, P. De Nardo, P. Ghirga, E. Gentilotti, R. Bellagamba, C. Tommasi, et al. Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine. Malar J. vol. 11, p. 91, 2012.

P. De Nardo, A. Oliva, M. L. Giancola, P. Ghirga, P. Mencarini, M. Bibas, et al. Haemolytic anaemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria. Infection. vol. 41, no. 4, pp. 863–865, 2013.

C. Hasegawa, M. Kudo, H. Maruyama and M. J. Kimura. Severe delayed haemolytic anaemia associated with artemether-lumefantrine treatment of malaria in a Japanese traveller. Journal of Infection and Chemotherapy. vol. 24, no. 3, pp. 216-219, Mar 2018. https://doi.org/10.1016/j.jiac.2017.10.008

Federal Ministry of Health (FmoH) and National Malaria Elimination Programme (NMEP). National malaria strategic plan 2014-2020. Abuja, Nigeria: FmoH and NMEP, 2014.

G. I. Olasehinde, D. O. Ojurongbe, O. J. Akinjogunla, L. O. Egwari and A. O. Adeyeba. Prevalence of malaria and predisposing factors to antimalarial drug resistance in Southwestern Nigeria. Res J Parasitol. vol. 10, no. 3, pp. 92–101, 2015.

D. T. Esan, A. A. Fasoro, O. E. Odesanya, T. O. Esan, E. F. Ojo and C. O. Faeji. Assessment of self-medication practices and its associated factors among undergraduates of a private university in Nigeria J Environ Public Health vol. 1, pp. 1-7, 2018. https://doi.org/10.1155/2018/5439079.

J. C. Chukwu. Traditional Igbo economy: challenges to growth and development. JCSD vol. 10, pp. 70-77, 2015.

S. C. Welle, O. Ajumobi, M. Dairo, M. Balogun, P. Adewuyi, B. Adedokun et al. Preference for artemisinin–based combination therapy among healthcare providers, Lokoja, North-Central Nigeria. Glob Health Res Policy. vol. 19, pp. 1-4, Jan 2019. Doi:10.1186/s41256-018-0092-9

F. T. Aweeka and P. I. German. Clinical pharmacology of artemisinin-based combination therapies. Clinical Pharmacokinetics vol. 47, p. 91, Sep 2008. https://doi.org/10.2165/00003088-200847020-00002

A. Camara, L. F. Moriarty, T. Guilavogui, P. S. Diakite, J. S. Zoumanigui, S. Sidibe, et al. Prescriber practices and patient adherence to artemisinin-based combination therapy for the treatment of uncomplicated malaria in Guinea, 2016. Malar J vol. 18, no. 1, p. 23, Jan 2019. Doi: 10.1186/s12936-019-2664-7.

M. E. Boel, M. J. Rijken, B. J. Brabin, F. Nosten and R. McGready. The epidemiology of postpartum malaria: a systematic review. Malar J vol. 11, p. 114, Apr 2012.

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

How to Cite
Ogefere, H., Idemudia, N., & Omoregie, R. (2020). Risk Factors For The Presence Of Artemisinin Antibodies Amongst Patients Undergoing Treatment For Malaria In Benin City, Nigeria. European Journal of Medical and Health Sciences, 2(3). https://doi.org/10.24018/ejmed.2020.2.3.279